Filter Results:
(1,253)
Show Results For
- All HBS Web
(1,253)
- People (5)
- News (175)
- Research (927)
- Events (6)
- Multimedia (12)
- Faculty Publications (758)
Show Results For
- All HBS Web
(1,253)
- People (5)
- News (175)
- Research (927)
- Events (6)
- Multimedia (12)
- Faculty Publications (758)
- 30 Mar 2012
- HBS Seminar
Matthew W. Emmens, Executive Chairman,Vertex Pharmaceuticals
- October 1992 (Revised March 1993)
- Supplement
ImmuLogic Pharmaceutical Corporation (B1): Malcolm Gefter
By: Josh Lerner
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry
Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (B1): Malcolm Gefter." Harvard Business School Supplement 293-067, October 1992. (Revised March 1993.)
- January 2006 (Revised May 2007)
- Supplement
Endo Pharmaceuticals (F): Appeals Court Ruling
By: Richard G. Hamermesh and Brian DeLacey
Hamermesh, Richard G., and Brian DeLacey. "Endo Pharmaceuticals (F): Appeals Court Ruling." Harvard Business School Supplement 806-082, January 2006. (Revised May 2007.)
- March 2015
- Case
Novartis Pharmaceuticals Corp: Redefining Success in the U.S. (A)
By: Gautam Mukunda, Thomas DeLong and Aldo Sesia
Over the course of a tumultuous weekend in April 2010, André Wyss was put in charge of Novartis Pharmaceuticals Corporation (NPC), the U.S. sales and marketing subsidiary of Novartis Pharma AG. He was brought in at a critical point in the organization's evolution with... View Details
Keywords: LEAD; Talent Management; Leadership And Change Management; Change Management; Organizational Change and Adaptation; Restructuring; Pharmaceutical Industry; United States
Mukunda, Gautam, Thomas DeLong, and Aldo Sesia. "Novartis Pharmaceuticals Corp: Redefining Success in the U.S. (A)." Harvard Business School Case 415-013, March 2015.
- January 2006 (Revised May 2007)
- Supplement
Endo Pharmaceuticals (E): Judge Stein Rules
By: Richard G. Hamermesh and Brian DeLacey
Hamermesh, Richard G., and Brian DeLacey. "Endo Pharmaceuticals (E): Judge Stein Rules." Harvard Business School Supplement 806-081, January 2006. (Revised May 2007.)
- March 1993 (Revised September 1995)
- Teaching Note
Note on Pharmaceutical Industry Regulation TN
Teaching Note for (9-792-002). View Details
- 2018
- Chapter
Pharmaceutical Trends, Not What They Seem
By: Kyle Myers and Mark Pauly
Myers, Kyle, and Mark Pauly. "Pharmaceutical Trends, Not What They Seem." In Managing Discovery in the Life Sciences: Harnessing Creativity to Drive Biomedical Innovation, by Philip A. Rea, Mark V. Pauly, and Lawton R. Burns, 18–42. Cambridge: Cambridge University Press, 2018.
- January 2006 (Revised May 2007)
- Supplement
Endo Pharmaceuticals (C): An "At Risk" Launch?
By: Richard G. Hamermesh and Brian DeLacey
Hamermesh, Richard G., and Brian DeLacey. Endo Pharmaceuticals (C): An "At Risk" Launch? Harvard Business School Supplement 806-066, January 2006. (Revised May 2007.)
- April 2015
- Supplement
Novartis Pharmaceuticals Corp: Redefining Success in the U.S. (B)
By: Gautam Mukunda, Thomas DeLong and Aldo Sesia
This (B) case describes the actions André Wyss, president of Novartis Pharmaceuticals Corporation, took in early 2012 to transform the company's General Medicines group and build its specialty medications, marketing the selling capabilities in the face of falling... View Details
Keywords: LEAD; Leadership And Change Management; Talent Management; Organizational Change and Adaptation; Leadership; Change Management; Talent and Talent Management; Pharmaceutical Industry; United States
Mukunda, Gautam, Thomas DeLong, and Aldo Sesia. "Novartis Pharmaceuticals Corp: Redefining Success in the U.S. (B)." Harvard Business School Supplement 415-049, April 2015.
- October 1992 (Revised March 1993)
- Supplement
ImmuLogic Pharmaceutical Corporation (C): April 1991
By: Josh Lerner
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry
Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (C): April 1991." Harvard Business School Supplement 293-071, October 1992. (Revised March 1993.)
- October 1992 (Revised April 1993)
- Supplement
ImmuLogic Pharmaceutical Corporation (B2): Henry McCance
By: Josh Lerner
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry
Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (B2): Henry McCance." Harvard Business School Supplement 293-068, October 1992. (Revised April 1993.)
Endogenous Productivity of Demand-Induced R&D: Evidence from Pharmaceuticals
When people want more new drugs, firms are happy to invest in ideas that cost more. And as they run out of "low hanging fruit" while demand keeps growing, R&D costs will naturally grow.
Abstract: We examine trends in the productivity of the... View Details
Abstract: We examine trends in the productivity of the... View Details
- 14 Mar 2014
- HBS Seminar
Jeremy M. Levin, former President and CEO, Teva Pharmaceutical Industries
- November 2006 (Revised November 2007)
- Case
Strategy in the Twenty First Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc.
By: David J. Collis and Troy Smith
The global pharmaceutical industry has gone through substantial changes in the last few decades and pharmaceutical firms face major challenges including headline-grabbing litigation, imminent patent expirations, new technologies, rising drug development costs, generic... View Details
Keywords: Mergers and Acquisitions; Growth and Development Strategy; Product Development; Research and Development; Corporate Strategy; Pharmaceutical Industry; United States
Collis, David J., and Troy Smith. "Strategy in the Twenty First Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc." Harvard Business School Case 707-509, November 2006. (Revised November 2007.)
- February 2014 (Revised June 2016)
- Case
Mylan Laboratories' Proposed Merger with King Pharmaceutical
By: Lucy White and Matt Kozlowski
Perry Capital owns shares in King and, to facilitate approval of the merger, buys shares in Mylan, whilst hedging out its economic exposure to Mylan's share price using derivatives. The price at which Mylan proposes to merge with King is generous to King shareholders,... View Details
Keywords: Mergers and Acquisitions; Voting; Ethics; Stock Shares; Investment; Lawsuits and Litigation; Ownership Stake
White, Lucy, and Matt Kozlowski. "Mylan Laboratories' Proposed Merger with King Pharmaceutical." Harvard Business School Case 214-078, February 2014. (Revised June 2016.)
- June 1983 (Revised November 1985)
- Background Note
World Pharmaceutical Industry: Prospects for the 1980s
Buzzell, Robert D. "World Pharmaceutical Industry: Prospects for the 1980s." Harvard Business School Background Note 583-168, June 1983. (Revised November 1985.)
- August 2012 (Revised January 2013)
- Module Note
Note on Pharmaceutical Reimbursement in the U.S.
By: Regina Herzlinger and Drew Cronin-Fine
- Article
Pharmaceutical Marketing Practices in the Third World
By: N. Craig Smith and John A. Quelch
Smith, N. Craig, and John A. Quelch. "Pharmaceutical Marketing Practices in the Third World." Special Issue on Quality of Life. Journal of Business Research 23, no. 1 (August 1991): 113–126.
- August 1983
- Case
CIBA-GEIGY Pharmaceuticals Division: Multinational Strategic Planning
Buzzell, Robert D. "CIBA-GEIGY Pharmaceuticals Division: Multinational Strategic Planning." Harvard Business School Case 584-018, August 1983.
- February 2014
- Teaching Note
Mylan Lab's Proposed Merger with King Pharmaceuticals
By: Lucy White
Perry Capital owns shares in King and, to facilitate approval of the merger, buys shares in Mylan, whilst hedging out its economic exposure to Mylan's share price using derivatives. The price at which Mylan proposes to merge with King is generous to King shareholders,... View Details